AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) fell 0.3% during mid-day trading on Thursday. The company traded as low as $2.75 and last traded at $2.89. 102,557 shares were traded during trading, an increase of 554% from the average daily volume of 15,685 shares. The stock had previously closed at $2.90.
AlloVir Stock Performance
The stock has a market capitalization of $14.57 million, a price-to-earnings ratio of -0.14 and a beta of 0.63. The firm’s fifty day simple moving average is $3.69 and its 200 day simple moving average is $4.72.
AlloVir Company Profile
AlloVir, Inc was a biotechnology company focused on developing allogeneic, virus-specific T-cell therapies for people whose immune systems are compromised, including recipients of organ or stem-cell transplants. Its research sought to address serious viral infections that can occur when patients cannot mount an effective immune response.
The company’s leading investigational product was posoleucel, also known as ALVR105, an “off-the-shelf” multivirus-specific T-cell therapy designed to target several viruses, including cytomegalovirus, Epstein-Barr virus, adenovirus, BK virus and human herpesvirus 6.
See Also
- Five stocks we like better than AlloVir
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
